Recombinant Human CD20/MS4A1 Protein (TrxA Tag) | PKSH030304

Recombinant Human CD20/MS4A1 Protein (TrxA Tag) | PKSH030304 | Gentaur US, UK & Europe Disrtribition

Synonyms: B1;Bp35;CD20;CVID5;LEU-16;MS4A1;MS4A2;S7

Active Protein: N/A

Activity: A DNA sequence encoding the human MS4A1 (NP_068769.2) (Ile141-Ser188) was expressed with a TrxA tag at the N-terminus.

Protein Construction: A DNA sequence encoding the human MS4A1 (NP_068769.2) (Ile141-Ser188) was expressed with a TrxA tag at the N-terminus.

Fusion Tag: N-TrxA

Species: Human

Expressed Host: E.coli

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Purity: > 80 % as determined by reducing SDS-PAGE.

Endotoxin: Please contact us for more information.

Stability and Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Molecular Mass: 23.9 kDa

Formulation: Lyophilized from sterile 50 mM Tris, 1 mM EDTA, 5% Trehalose, 5% Mannitol, 0.01% Tween-80, pH 8.0.

Reconstitution: Please refer to the printed manual for detailed information.

Background: CD20 (membrane-spanning 4-domains; subfamily A; member 1); also known as MS4A1; is a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. CD20 / MS4A1 is expressed on all stages of B cell development except the first and last. CD20 / MS4A1 is present from pre-pre B cells through memory cells; but not on either pro-B cells or plasma cells. It is a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. CD20 / MS4A1may be involved in the regulation of B-cell activation and proliferation. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5(CVID5). CVID5 is a primary immunodeficiency characterized by antibody deficiency; hypogammaglobulinemia; recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range; but can be low.Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

Research Area: Cancer, immunology, Stem cells